オプションチェーンは、Eupraxia Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Eupraxia Pharmaceuticalsの市場センチメントを評価します。.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) 株価情報, オプションチェーン

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc Ordinary Shares

Macro Economic Events

News

Global

Economics

Bessent Says We Will See If China Wants To Be A Responsible Partner

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated
Presentation at the Phoenix Best Science Series by HonorHealth Research Institute on June 27, 2025 in Scottsdale, Arizona
MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary TRBC product discovery and development platform technology.
The TRBC technology enabled the Company to construct T-cell engagers that not only target cancer antigens and CD3 activation of effector T cells, but also simultaneously reduce the immunosuppression in tumor microenvironment. Such immunosuppression plays a pivotal role in reducing effector T-cell infiltration and anti-tumor efficacy in solid tumors. The Company's two lead T-cell engagers target tissue factor and mesothelin, which are proven solid tumor antigens. These product candidates exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at dose levels that are well tolerated. Dr. Hing C. Wong, Founder and CEO of the Company, will present the details of these IND-enabling studies as an invited speaker for the Phoenix Best Science Series, hosted by HonorHealth Research Institute, located at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona, on June 27, 2025.

HCWB

HCW Biologics' Scientists Develops Second-Gen, Multi-Specific T-Cell Engagers Against Solid Tumors Using Proprietary TRBC Product Discovery And Development Platform Technology

WIIM

INMB

INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.

Mixed Martial Arts Group shares are trading higher after the company announced it partnered with Morphotech for a blockchain and AI crypto rewards platform.

Lotus Technology shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

CNXC

Concentrix shares are trading lower after the company reported a Q2 adjusted EPS miss and narrowed its FY25 adjusted EPS guidance.

AOUT

American Outdoor Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

CRMD

CorMedix shares are trading lower after the company announced an $85 million public offering.

RILY

B. Riley Financial shares are trading higher after the company sold its advisory services businesses, GlassRatner Advisory & Capital Group and B. Riley Farber Advisory, to funds managed by TorQuest Partners for $117.8 million.

Canaccord Genuity analyst Joseph Vafi maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

Price Target

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Maintains Buy on Core Scientific, Maintains $17 Price Target

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk endorsed&nbsp;Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Satya Nadella&#8217;s&nbsp;perspective on&nbsp;the practical impact of AI, emphasizing its&nbsp;benefits to sectors like healthcare,&nbsp;education, and productivity.
What Happened: Musk, on X, supported Nadella&#8217;s views on AI&#8217;s progress, which were shared in a post by Nadella on June 25, 2025. Nadella, the CEO of&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), had stressed the importance of AI&#8217;s real-world outcomes over technical benchmarks at Y Combinator&#8217;s&nbsp;AI Startup School wherein Elon Musk commented &#8220;True&#8221;. Nadella stated that AI must produce results that are &#8220;socially useful.&#8221;
This shift in focus aligns with recent studies indicating AI&#8217;s&nbsp;potential to enhance GDP growth&nbsp;by addressing real-world challenges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">True <a href="https://t.co/iFlmTUzLwx">https://t.co/iFlmTUzLwx</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1938086636941939098?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;If we really are not creating social surplus, economic surplus, as measured by countries and communities, we just can&#8217;t consumer energy.&#8221; stated Nadella. 
&#8220;The real question in the next five years is we&#8217;ve got to produce enough products that are creating great value,&#8221; he added.
He also pointed out&nbsp;that the true measure of&nbsp;AI&#8217;s progress lies in&nbsp;its ability to improve real-world&nbsp;outcomes rather than just achieving&nbsp;technical benchmarks. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46131453/bitcoin-ethereum-rangebound-dogecoin-dips-amid-potential-july-tariff-deadline-extension-analyst-predicts-btcs-next-big-move-once-it-breaks-out-of-this-range" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Rangebound, Dogecoin Dips Amid Potential July Tariff Deadline Extension: Analyst Predicts BTC&#8217;s &#8216;Next Big Move&#8217; Once It Breaks Out Of This Range </a>
Why It Matters:&nbsp;Musk&#8217;s endorsement of Nadella&#8217;s view on AI&#8217;s real progress comes at a time when the tech industry is witnessing a shift towards focusing on&nbsp;the practical impact of AI.
CEO Satya Nadella believes that while AI is already <a href="https://www.benzinga.com/markets/tech/25/06/46111393/ai-is-already-speeding-up-discoveries-in-chemistry-and-physics-but-satya-nadella-says-the-real-breakthrough-will-come-when-we-add-quantum-computing-to-the-mix">driving major</a> scientific breakthroughs, its full transformative potential will be unlocked with the integration of quantum computing. Meanwhile, the growing role of AI in healthcare was highlighted, with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partnering with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to speed up drug discovery and development. 
However, Wall Street remains divided on AI's future—while some investors are optimistic about its disruptive potential, others express concerns over associated risks and the lack of transparency in how it is being managed.
On a year-to-date basis, ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) climbed 24.85% and 13.05%, respectively. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46127671/amazon-loses-top-ai-leader-in-high-stakes-talent-shuffle">Amazon Loses Top AI Leader In High-Stakes Talent Shuffle </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARKK

MSFT

NVDA

TSLA

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) will release earnings results for the first quarter after the <a href="https://www.benzinga.com/quote/STZ/earnings">closing bell on Tuesday, July 1.</a>
Analysts expect the company to report quarterly earnings at $3.29 per share, down from $3.57 per share in the year-ago period. Constellation Brands projects to report quarterly revenue at $2.56 billion, compared to $2.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, Barclays analyst Lauren Lieberman maintained a Constellation Brands rating of Overweight and lowered the price target from $207 to $202. JP Morgan analyst Andrea Teixeira maintained the stock with a Neutral rating and cut the price target from $194 to $170.
With the recent buzz around Constellation Brands, some investors may be eyeing potential gains from the company's dividends too. As of now, Constellation Brands offers an annual dividend yield of 2.53%, which is a quarterly dividend amount of $1.02 per share ($4.08 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $237,302 or around 1,471 shares. For a more modest $100 per month or $1,200 per year, you would need $47,428 or around 294 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.08 in this case). So, $6,000 / $4.08 = 1,471 ($500 per month), and $1,200 / $4.08 = 294 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
STZ Price Action: Shares of Constellation fell 0.1% to close at $161.32 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a></li>
</ul>
Photo: The Image Party/Shutterstock

Earnings

Long Ideas

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From Constellation Brands Stock Ahead Of Q1 Earnings

Chinese electric vehicle manufacturer Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) stock traded lower on Friday after the company cut its delivery outlook for the <a href="https://www.benzinga.com/pressreleases/25/06/g46133821/li-auto-inc-updates-second-quarter-delivery-outlook" target="_blank" rel="noreferrer noopener">second quarter of 2025</a>.
This adjustment closely follows <a href="https://www.benzinga.com/markets/asia/25/06/46132552/telsla-model-y-rival-xiaomi-yu7-suv-receives-nearly-300000-orders-in-1-hour-in-china">Xiaomi&#8217;s successful YU7 SUV</a> launch, which aggressively undercut rivals like Tesla&#8217;s Model Y and intensified competition in the Chinese EV market.
Li Auto now anticipates delivering approximately 108,000 vehicles in the second quarter of 2025, which represents a 0.5% year-on-year decline.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/45881963/tesla-supplier-catl-hits-milestone-with-1-million-battery-packs-delivered-to-li-auto" rel="noreferrer noopener">Tesla Supplier CATL Hits Milestone With 1 Million Battery Packs Delivered To Li Auto</a>
This is a significant reduction from its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45667278/li-auto-q1-vehicle-deliveries-jump-15-continues-high-cash-burn" rel="noreferrer noopener">previous forecast</a> of 123,000-128,000 vehicles, which would have represented a 13.3%-17.9% year-on-year increase.
For context, Li Auto reported total vehicle deliveries of 108,581 units in the fiscal <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40595804/chinese-ev-maker-li-auto-q2-earnings-eps-beat-25-deliveries-growth-margin-struggles-and-more" rel="noreferrer noopener">second quarter of 2024</a>.
Li Auto attributes this adjustment to the temporary impact of an ongoing sales system upgrade, a strategic move intended to support its long-term growth.
It expressed conviction in completing its organizational upgrade before the launch of Li i8, enabling it to embrace the new product cycle effectively. The stock gained 53% in the last 12 months.
Li Auto <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45691082/tesla-rival-li-auto-will-release-2-new-suvs-this-year-ceo-li-xiang-hints-at-companys-first-sedan" rel="noreferrer noopener">plans to launch</a> two new SUVs in 2025 and may debut its first sedan if market conditions allow.
During its Q1 2025 earnings call, the company shared details about the Li i8, its first all-electric SUV designed for six passengers, and the smaller five-seat Li i6. Li Auto aims to release the i8 in July and the i6 in August.
The broader geopolitical landscape, particularly evolving U.S.-China trade relations, is influencing the semiconductor and EV sectors.
In the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45902627/us-listed-chinese-tech-and-ev-stocks-slide-as-trump-confirms-china-trade-deal" rel="noreferrer noopener">second week of June</a>, President&nbsp;Donald Trump confirmed a&nbsp;China trade deal&nbsp;after two days of negotiations in London, which sent the U.S.-listed Chinese stocks down. The U.S. plans to apply 55% tariffs on selected Chinese imports, while China will impose a 10% tariff rate on U.S. goods.
According to reports, U.S. and Chinese officials met in London for trade talks, which likely focused on rare earth minerals. Rare earth elements play significant roles in everything from smartphones to electric vehicles to fighter jets. The U.S. depends on China for ~70% of its imports of rare earth elements.
Furthermore, U.S. restrictions on China&#8217;s access to Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) technology have <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report" rel="noreferrer noopener">spurred Chinese automakers</a>, including Li Auto, to accelerate efforts to replace foreign semiconductors with domestic alternatives in their vehicles by 2027. At least two Chinese brands are reportedly aiming for mass production of cars using 100% domestic chips by 2026.
Price Action: LI stock is trading lower by 3.36% to $27.07 premarket at&nbsp;last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46116924/cyngn-stock-soars-135-after-partnering-with-nvidia-to-showcase-autonomous-industrial-vehicles" target="_blank" rel="noreferrer noopener">Autonomous Vehicle Solutions Provider Cyngn Stock Soars After Partnering With Nvidia &#8211; Here&#8217;s Why (UPDATED)</a></li>
</ul>
Photo by Robert Way via Shutterstock

Guidance

Movers

Tech

China's Li Auto Cuts Outlook As Xiaomi Challenges EV Giants

FOXO

FOXO Technologies Designates Series E Preferred Stock With Dual Dividends As Acquisition Currency And Capital Raise Tool

Nike shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

Telsey Advisory Group analyst Cristina Fernandez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Market Perform and maintains $70 price target.

Telsey Advisory Group Maintains Market Perform on Nike, Maintains $70 Price Target

Company Expects to Record Gain on Sale of Approximately $66 Million in Q2 Financial Results
LOS ANGELES, June 27, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) ("BRF" or the "Company"), a diversified financial services company, today announced it has sold its advisory services business, GlassRatner Advisory &amp; Capital Group, LLC (dba B. Riley Advisory Services) and B. Riley Farber Advisory Inc. (collectively "GlassRatner"), to funds managed by TorQuest Partners ("TorQuest") for $117.8 million.
BRF expects to record a gain on the sale of GlassRatner, which it acquired in August 2018, of approximately $66 million.

B. Riley Financial Sells Advisory Services Business, GlassRatner Advisory & Capital Group And B. Riley Farber Advisory To Funds Managed By TorQuest Partners For $117.8M

Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock.&nbsp; The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions.&nbsp; Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remaining shares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer.&nbsp; Turnstone stockholders holding approximately 25.2% of Turnstone common stock have signed support agreements under which such stockholders have agreed to tender their shares in the Offer and support the merger transaction.&nbsp; The merger transaction is expected to close in August 2025.

TSBX

XOMA Royalty To Acquire Turnstone Biologics For $0.34 Per Share Plus CVR In August-Targeted Merger Deal

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $3 price target.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $3 Price Target

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) &#8220;very, very much,&#8221; adding that it is one of the few stocks in that group that he <a href="https://www.benzinga.com/quote/MPC">actually wants to own</a>.
Supporting his view, the company, on May 6, posted first-quarter total revenues and other income of $31.85 billion topping the consensus of $29.58 billion. Adjusted EPS loss stood at $(0.24), down from $2.58 a year earlier, beating the analyst consensus estimate of $(0.53).
Cramer said, &#8220;I have seen these speculative stocks go up and up, and I'm not going to make you sell Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) when a headline would cause that stock to double.&#8221;
On the earnings front, Aurora Innovation, on May 8, posted a first-quarter GAAP loss of 12 cents per share, in line with estimates.
Cramer said he is going with Brad Jacobs [Chairperson of QXO], when asked about QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>).
QXO, on June 20, proposed to acquire GMS for $95.20 per share in cash.
The Mad Money host said he likes Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), adding, &#8220;You got a good one there.&#8221;
Lending support to his choice, Truist Securities analyst Matthew Coad initiated coverage on Toast on June 2 with a Buy rating and announced a price target of $48.
Price Action:
<ul class="wp-block-list">
<li>Marathon Petroleum shares rose 1.1% to settle at $167.52 on Thursday.</li>
<li>Aurora Innovation shares gained 2.1% to close at $5.40.</li>
<li>QXO gained 1.4% to settle at $24.12 on Thursday.</li>
<li>Toast shares gained 2.4% to close at $42.49.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a></li>
</ul>
Image created using photos from Shutterstock.

Media

TOST

Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own

Press Releases

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Health Care

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

"Bear-Pit Session" Highlights Peterson Capital's Canada Growth Conference in Montreal

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Comments

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル